Current and upcoming Clinical Trials
DUE TO COVID-19 OUR TRIALS ARE CURRENTLY ONHOLD
Current trials - RECRUITING NOW
- AES - INVESTIGATIONS OF IMMUNE MECHANISMS OF THE AIRWAY EPITHELIUM. Airway epithelial cells are the building blocks that make up the surface of the airways, known as the epithelium. This study aims to investigate defence mechanisms of these airway epithelial cells from patients with airways diseases. The airway epithelium has been shown to play roles in immunity, inflammation, tissue remodelling and host defence. Patients with inflammation in their airways are more susceptible to respiratory infections than healthy individuals, with epithelial cells proven to function differently in both asthma and Chronic Obstructive Pulmonary Disease (COPD) compared to health. The airway epithelium is the first place in the airways to come into contact with inhaled bacteria. It can communicate with other cells in the airway (immune cells) to kill the bacteria and prevent infection. We are particularly interested in discovering why some patients experience prolonged infections while others don’t. In the laboratory we will isolate cells from the samples you gift, and measure their responses when we add bacteria and other stimulants.
- STIFLE - Investigating Asthma inflammation in patients taking daily Asthma medication. Measurements will be performed daily by patients at home using devices which will connect to a smartphone.
- Are you aged over 18
- Have you been diagnosed with Asthma for longer than 6 months
- Can you complete daily measurements at home for the next 6 months
- Have you needed to use oral steroids for worsening asthma symptoms
If you are interested in taking part please do not hesitate to contact one of our research nurses on 01865 227242.
Ongoing trials (Recruitment finished):
- CASCADE - A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults with Inadequately Controlled Asthma on Inhaled Corticosteroids and at least one additional asthma controller.
- ABRA STUDY- The use of Benralizumab, an interleukin-5 receptor-α monoclonal antibody as treatment of acute exacerbations of airways disease .
- CORAL STUDY - A 12-week exploratory study to characterise the relationship between changes in Inflammatory markers, lung function, symptoms and reliever use in Chronic Obstructive Pulmonary Disease Patients.
- RESOLUTE - A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils
- BAYER COUGH STUDY - Study 20393, BAY 1817080 Randomized, double-blind, parallel group, Phase 2b dose-finding, efficacy and safety study of 12-week twice daily oral administration of BAY 1817080 compared to placebo in the treatment of refractory and/or unexplained chronic cough (RUCC).
- SHIONOGI COUGH STUDY